Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael L. Wang, Jon E. Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostic, Daniel Li, Yeonhee Kim, Tanya Siddiqi
Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Nebraska Medical Center, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, University of Alabama at Birmingham, University of Colorado Anschutz, University of Colorado Denver, Fred Hutch Cancer Center, University of California, San Francisco, University of Pittsburgh Medical Center, Northside Hospital, Levine Cancer Institute, Juno Therapeutics (United States), City Of Hope National Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2987075075